Artimplant postpones Year-End Report

The Board of Directors has decided to postpone the publication of Artimplant's
Year-End Report until February 27, 2013. The original publication date was
February 1, 2013.
The reason for the change is the ongoing complaints in the USA and the related
insurance situation. As stated previously, it is Artimplant's understanding that
there is perfectly adequate insurance cover for the costs attributable to the
complaints in the USA. However, the parties involved, comprising two insurance
companies and one insurance broker, are in disagreement regarding how the costs
are to be divided between them. As Artimplant is a contracting party with all
three, it is incumbent on Artimplant to continue to pursue the matter. During
the summer, Artimplant entered into an agreement with the insurance companies
and the insurance broker, which means that until further notice these parties
will reimburse Artimplant in advance for the complaint costs that have arisen
since June 1, 2012 and until the division of liability can be clarified
conclusively.

Negotiations are taking place between all the parties to reach an agreement. If
the parties are unable to reach an agreement in this matter soon, Artimplant
will be obliged to call for arbitration proceedings in the matter against the
insurance companies and the insurance broker. Possible arbitration proceedings
would of course be a source of uncertainty for all parties involved.

In the light of the above, the Board of Directors is of the opinion that there
is uncertainty regarding the valuation of certain items in the final accounts
and the Company's financial position and it has therefore opted to wait before
publishing the Year-End Report until the current negotiations between the
parties have been concluded.
Västra Frölunda, January 31, 2013

Board of Directors



For further information, please contact:
Kjell Thörnbring, CEO
E-mail: kjell.thornbring@artimplant.com
Telephone: +46 703 119 025

Anders Cedronius, Chairman of the Board
Telephone:+46 706-422 745

Further information is available at www.artimplant.com where you can also
subscribe to future press releases; www.artimplant.com/investors-media/subscribe
-to-press-releases.html
Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedics. We restore health through the development, production and marketing
of degradable implants that regenerate body functions and improve quality of
life. Our products, made from Artelon®, meet unmet clinical needs and are
marketed in a growing number of therapy areas. Artimplant produces implants for
treatment of osteoarthritis in hands and feet as well as shoulder and other soft
tissue injuries.

Artimplant is a public company, listed on NASDAQ OMX Stockholm in the Small Cap
segment and in the healthcare sector.
Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting on the Company's business, including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.

This is information that Artimplant will make public pursuant to the Swedish
Financial Instruments Act and the Swedish Securities Exchange and Clearing
Operations Act and/or stock market agreements. Information was made available
for publication on January 31, 2013 at 11am (Swedish time).